InvestorsHub Logo
Followers 59
Posts 2197
Boards Moderated 4
Alias Born 04/28/2019

Re: None

Saturday, 05/04/2019 6:04:26 PM

Saturday, May 04, 2019 6:04:26 PM

Post# of 4876
Compensated Awareness Post View Disclaimer
Time to be BULLISH on Gilead Sciences.

Gilead reported earnings on Thursday and it may be finally turning the corner. GILD was considered a one trick pony due to the success of its Hepatitis drugs, which unfortunately have starting to drop in revenue. That decline has been meet with a rising revenue stream from new HIV treatments, which tend to be longer term treatments than Hepatitis cases. As a result of recent acquisitions, Oncology is also a growing revenue stream with Yescarta more than doubling revenue to $96m in the first quarter. GILEAD also has a sizable cash at hand of $30 Billion along with a very strong balance sheet . Analysts have a overweight rating on the stock and a average price target of $81, we expect some upgrades in the days to come. NASDAQ:GILD


Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!

IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GILD News